ACADIA Pharmaceuticals Inc.

ACAD · NASDAQ

ACAD is no longer the kind of biotech where everything hangs on a single trial. The sharper question is whether NUPLAZID and DAYBUE can fund a third CNS franchise before concentration, payer pressure, and pipeline risk catch up.

Follow Add to Watchlist Ask Question

NASDAQ ACAD Coverage Bootstrap Biopharma Neurology Rare Disease

Latest ReportMay 13, 2026ACADIA (ACAD): two drugs, $1.25 billion guidance, and one Alzheimer readout that can change the stockView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.